Fig. 6.
PK/PD with anti-mouse TfR/BACE1 antibody. Quantification of Aβ1–40 A, B and huIgG concentrations C, D in C57BL/6 J WT mouse brains A, C and plasma B, D at day D 1, 3 and 7 after a single intravenous injection of 1A11AM-aGFP or 1A11AM-Nb62 (167 nmol/kg; low dose: 16.7 nmol/kg). Bar graphs represent mean ± SEM (n = 3–5 per group). Statistical test: two-way ANOVA with Sidak’s multiple comparisons test. A and B Significant treatment*day interaction effect for brain (**p = 0.0014), but not for plasma (ns = 0.0529). C and D Significant treatment*day interaction effect for both brain (****p < 0.0001) and plasma (***p < 0.0002). E) HuIgG brain over plasma ratio. Significant overall treatment effect (**p = 0.0027). Significant overall treatment effect for A, C, D, E and significant effect over time for A, B, C, D not shown